Difference between revisions of "Team:CPU CHINA"
| Line 3: | Line 3: | ||
<head> | <head> | ||
| − | |||
| − | |||
<script src="https://cdn.bootcss.com/jquery/1.9.1/jquery.min.js"></script> | <script src="https://cdn.bootcss.com/jquery/1.9.1/jquery.min.js"></script> | ||
<script src="https://cdn.bootcss.com/onepage-scroll/1.3.1/jquery.onepage-scroll.min.js"></script> | <script src="https://cdn.bootcss.com/onepage-scroll/1.3.1/jquery.onepage-scroll.min.js"></script> | ||
<link rel="stylesheet" href="https://cdn.bootcss.com/onepage-scroll/1.3.1/onepage-scroll.min.css" type="text/css"> | <link rel="stylesheet" href="https://cdn.bootcss.com/onepage-scroll/1.3.1/onepage-scroll.min.css" type="text/css"> | ||
| + | |||
| + | <link rel="stylesheet" href="https://2017.igem.org/Team:CPU_CHINA/css/home?action=raw&ctype=text/css"> | ||
| + | <link rel="stylesheet" href="https://2017.igem.org/Team:CPU_CHINA/css/description?action=raw&ctype=text/css"> | ||
</head> | </head> | ||
| Line 25: | Line 26: | ||
<div class="body-container"> | <div class="body-container"> | ||
| − | <center class="pagee | + | <center class="pagee pagee1"> |
<p><br> <br></p> | <p><br> <br></p> | ||
<p><br> <br></p> | <p><br> <br></p> | ||
| Line 31: | Line 32: | ||
</center> | </center> | ||
| − | <center class="pagee | + | <center class="pagee pagee2"> |
<p><br> <br></p> | <p><br> <br></p> | ||
<h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5> | <h5 style="padding: 0px; margin: 5px;">Our HEAD-Treg</h5> | ||
| Line 37: | Line 38: | ||
</center> | </center> | ||
| − | <center class="pagee | + | <center class="pagee pagee3"> |
<p><br> <br></p> | <p><br> <br></p> | ||
<p><br> <br></p> | <p><br> <br></p> | ||
Revision as of 14:57, 1 November 2017
Our HEAD-Treg
Description
Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
It is of great essence to develop a novel cell-targeted therapy for RA
because there is no radical cure
for RA for the time being.
To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy.
FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified
utilizing a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated with RA.
Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the
inflammatory environment, which enables them to play their role of immunosuppression in lesions more
efficiently and more stably.
These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect.
